DIVIS LABORATORIES | NATCO PHARMA | DIVIS LABORATORIES/ NATCO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 59.2 | 34.0 | 174.3% | View Chart |
P/BV | x | 13.6 | 4.8 | 282.5% | View Chart |
Dividend Yield | % | 0.4 | 0.7 | 64.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DIVIS LABORATORIES Mar-19 |
NATCO PHARMA Mar-19 |
DIVIS LABORATORIES/ NATCO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,639 | 849 | 193.1% | |
Low | Rs | 1,115 | 557 | 200.2% | |
Sales per share (Unadj.) | Rs | 186.3 | 573.8 | 32.5% | |
Earnings per share (Unadj.) | Rs | 51.0 | 176.0 | 29.0% | |
Cash flow per share (Unadj.) | Rs | 57.3 | 198.2 | 28.9% | |
Dividends per share (Unadj.) | Rs | 16.00 | 6.25 | 256.0% | |
Dividend yield (eoy) | % | 1.2 | 0.9 | 130.7% | |
Book value per share (Unadj.) | Rs | 261.8 | 842.7 | 31.1% | |
Shares outstanding (eoy) | m | 265.47 | 36.50 | 727.3% | |
Bonus/Rights/Conversions | - | BB | - | ||
Price / Sales ratio | x | 7.4 | 1.2 | 603.3% | |
Avg P/E ratio | x | 27.0 | 4.0 | 676.6% | |
P/CF ratio (eoy) | x | 24.0 | 3.5 | 677.4% | |
Price / Book Value ratio | x | 5.3 | 0.8 | 630.7% | |
Dividend payout | % | 31.4 | 3.6 | 884.2% | |
Avg Mkt Cap | Rs m | 365,592 | 25,660 | 1,424.8% | |
No. of employees | `000 | 11.8 | 5.0 | 239.0% | |
Total wages/salary | Rs m | 5,423 | 3,559 | 152.4% | |
Avg. sales/employee | Rs Th | 4,175.1 | 4,225.3 | 98.8% | |
Avg. wages/employee | Rs Th | 457.7 | 718.0 | 63.8% | |
Avg. net profit/employee | Rs Th | 1,141.8 | 1,295.9 | 88.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 49,463 | 20,945 | 236.2% | |
Other income | Rs m | 1,556 | 1,302 | 119.5% | |
Total revenues | Rs m | 51,019 | 22,247 | 229.3% | |
Gross profit | Rs m | 18,718 | 7,948 | 235.5% | |
Depreciation | Rs m | 1,689 | 810 | 208.5% | |
Interest | Rs m | 35 | 193 | 18.1% | |
Profit before tax | Rs m | 18,551 | 8,247 | 224.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 5,023 | 1,823 | 275.6% | |
Profit after tax | Rs m | 13,527 | 6,424 | 210.6% | |
Gross profit margin | % | 37.8 | 37.9 | 99.7% | |
Effective tax rate | % | 27.1 | 22.1 | 122.5% | |
Net profit margin | % | 27.3 | 30.7 | 89.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 46,501 | 23,472 | 198.1% | |
Current liabilities | Rs m | 8,468 | 7,287 | 116.2% | |
Net working cap to sales | % | 76.9 | 77.3 | 99.5% | |
Current ratio | x | 5.5 | 3.2 | 170.5% | |
Inventory Days | Days | 131 | 92 | 141.9% | |
Debtors Days | Days | 86 | 88 | 97.3% | |
Net fixed assets | Rs m | 25,797 | 18,648 | 138.3% | |
Share capital | Rs m | 531 | 365 | 145.5% | |
"Free" reserves | Rs m | 68,962 | 34,525 | 199.7% | |
Net worth | Rs m | 69,493 | 30,760 | 225.9% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 80,383 | 43,031 | 186.8% | |
Interest coverage | x | 531.0 | 43.7 | 1,214.3% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.5 | 126.4% | |
Return on assets | % | 16.9 | 15.4 | 109.7% | |
Return on equity | % | 19.5 | 20.9 | 93.2% | |
Return on capital | % | 26.7 | 27.4 | 97.5% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 24.6 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 12,187 | NA | - | |
Fx inflow | Rs m | 41,238 | 11,536 | 357.5% | |
Fx outflow | Rs m | 12,405 | 2,939 | 422.1% | |
Net fx | Rs m | 28,833 | 8,597 | 335.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 9,543 | 6,688 | 142.7% | |
From Investments | Rs m | -6,854 | -6,122 | 112.0% | |
From Financial Activity | Rs m | -2,459 | -509 | 483.2% | |
Net Cashflow | Rs m | 230 | 66 | 347.9% |
Indian Promoters | % | 52.0 | 52.0 | 99.9% | |
Foreign collaborators | % | 0.0 | 1.5 | - | |
Indian inst/Mut Fund | % | 11.8 | 7.8 | 150.5% | |
FIIs | % | 19.0 | 16.6 | 114.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.2 | 26.0 | 66.2% | |
Shareholders | 31,796 | 25,395 | 125.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DIVIS LABORATORIES With: ELDER PHARMA FDC SUN PHARMA STRIDES PHARMA SCIENCE TTK HEALTHCARE
Compare DIVIS LABORATORIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More